

## **Effectiveness of Group Cognitive Therapy for Social Anxiety Disorder in Routine Care**

Colhoun, Helen; Kannis-Dymand, Lee; Rudge, Marion; Le Compte, Dianne; O'Flaherty, Sarah J.; Gilbert, Claire; Jones, Monique; Harrow, Sarah-Eve; Chambers, Ron; Woolcock, Colette; MacLeod, Juliet; Lovell, Geoff; Bell, Caroline

*Published in:*  
Behaviour Change

*Publication date:*  
2020

*The re-use license for this item is:*  
CC BY-NC-ND

*This document version is the:*  
Peer reviewed version

*The final published version is available direct from the publisher website at:*  
[10.1017/bec.2020.19](https://doi.org/10.1017/bec.2020.19)

**Find this output at Hartpury Pure**

*Citation for published version (APA):*

Colhoun, H., Kannis-Dymand, L., Rudge, M., Le Compte, D., O'Flaherty, S. J., Gilbert, C., Jones, M., Harrow, S.-E., Chambers, R., Woolcock, C., MacLeod, J., Lovell, G., & Bell, C. (2020). Effectiveness of Group Cognitive Therapy for Social Anxiety Disorder in Routine Care. *Behaviour Change*, 38(2).  
<https://doi.org/10.1017/bec.2020.19>

**Effectiveness of Group Cognitive Therapy for Social Anxiety Disorder in  
Routine Care**

Helen Colhoun <sup>a</sup>, Lee Kannis-Dymand <sup>a,b,c</sup>, Marion Rudge <sup>a</sup>, Dianne Le Compte  
<sup>a</sup>, Sarah J. O'Flaherty <sup>b</sup>, Claire Gilbert <sup>a</sup>, Monique Jones <sup>a,b</sup>, Sarah-Eve Harrow <sup>a</sup>, Ron  
Chambers <sup>a</sup>, Colette Woolcock <sup>a</sup>, Juliet Macleod <sup>a</sup>, Geoff P Lovell <sup>c,d</sup>, Caroline Bell <sup>e</sup>

<sup>a</sup> Anxiety Disorders Service, CDHB, Christchurch, New Zealand. <sup>b</sup> Sunshine  
Coast Mind & Neuroscience - Thompson Institute, University of the Sunshine Coast,  
Queensland, Australia. <sup>c</sup> University of the Sunshine Coast, Discipline of Psychology,  
School of Health and Behavioural Science, Queensland, Australia. <sup>d</sup> Department of  
Sport, Hartpury University, Gloucestershire, UK <sup>e</sup> Christchurch School of Medicine and  
Health Sciences, University of Otago, Christchurch, New Zealand

**Address for correspondence:** Lee Kannis-Dymand, PhD; PG.Dip.Clin.Psych;  
Oxford PG.Dip.Cog.Therapy. Senior Lecturer, USC / Sunshine Sunshine Coast Mind &  
Neuroscience - Thompson Institute, 12 Innovation Parkway, Birtinya, QLD 4557,  
Australia. Lkannisd@usc.edu.au

Social anxiety disorder (SAD) is a prevalent chronic condition with a large demand for treatment. This community outpatient study examined the effectiveness of a group intervention version of the established one-to-one cognitive therapy derived from the Clark and Wells model for SAD. Questionnaires were completed pre-treatment and post-treatment for SAD symptoms (Social Phobia Scale, Social Interaction Anxiety Scale), depressive symptoms (BDI-II), self-focused attention, safety behaviours (Social Phobia Weekly Summary Scale and Subtle Avoidance Frequency Examination, and impaired functioning (Work and Social Adjustment Scale). From an initial sample of 159 participants, 101 completed at least seven of the nine weekly group sessions ( $M_{\text{age}} = 34.1$  years,  $SD_{\text{age}} = 10.8$  years, 53% female). Significant improvements were demonstrated on all measures. Large effect sizes were found for social anxiety symptoms and safety behaviour use. Self-focused attention depressive symptoms and impaired functioning had moderate effect sizes. Effect sizes for anxiety ( $d = 1.00$  and  $1.32$ ) and mood measures ( $d = 0.71$ ) were as high, or in some cases, higher than previous group treatment studies. Results suggest group cognitive therapy for SAD based on the Clark and Wells model is effective in a clinical setting for individuals with moderate/severe and treatment resistant social anxiety.

*Keywords:* social anxiety disorder, group cognitive therapy, cognitive behaviour therapy

## **Introduction**

Social anxiety disorder (SAD) is the marked fear or anxiety about social situations in which the individual may be exposed to the possible scrutiny of others

(American Psychiatric Association, 2013). It affects a sizeable proportion of the population, with an estimated lifetime prevalence of 12.1% and a 12-month prevalence of 7.1% in the USA (Ruscio et al., 2008). Other countries report similar 12-month rates (Iancu et al., 2006); such as 4.7% in Australia (Slade, Johnston, Oakley Brown, Andrews, & Whiteford, 2009), 5.1% in New Zealand (Ministry of Health, 2012), and up to 7.9% in European nations (Wittchen et al., 2011). The average onset age for SAD is early adolescence (Ollendick & Hirshfeld-Becker, 2002), with the condition generally following a chronic and unremitting course across the life span (Albano & Hayward, 2004).

Despite the prevalence and chronic course of SAD, there is often limited time and resources to provide treatment (Goldin et al., 2016). The National Institute for Health and Care Excellence (NICE, 2013) recommends individual cognitive behaviour therapy (CBT) as the first-line treatment. Further support for this recommendation was provided by a recent meta-analysis of 101 trials of psychological and pharmacological interventions for SAD ( $n = 13,164$ ) (Mayo-Wilson et al., 2014). A corresponding economic analysis similarly reported that individual CBT (based on the Clark and Heimberg models) was the most cost-effective (Mavranouzouli et al., 2015). While there are a number of alternative approaches to delivering cognitive behaviour therapy (CBT), such as internet based and intensive treatments, results of the Mayo et al. review concluded that individual CBT, including cognitive therapy based on Clark and Wells (1995) model, consistently demonstrated the greatest effect sizes. Furthermore, that group CBT compared favourably with individual approaches (Mayo-Wilson et al., 2014). However, despite the reported effectiveness of group-based CBT, this treatment approach does have potential limitations, for example, lack of individualisation in terms

of treatment plans and strength of resulting therapeutic relationships (Hauksson, Ingibergsdóttir, Gunnarsdóttir, & Jónsdóttir, 2017; Sochting, 2014).

Clark and Wells (1995) Cognitive Therapy for Social Anxiety Disorder (hereinafter referred to as CT-SAD) uses a wider range of therapeutic procedures, which aim to reverse the maintaining processes specified in the Clark and Wells model (Clark et al., 2006). For example, participants identify and test cognitive predictions during behavioural experiments where safety behaviours are dropped and later feared outcomes are intentionally carried out. Feared outcomes may include sweating, talking about a possibly boring topic, or pausing during conversation. Additional exercises encourage the participant to transfer their attention from themselves to the external environment in order to identify information that challenges their negative self-beliefs and to reduce self-focused attention.

Reflecting the demand for treatment coupled with limited health service resources, there has been increasing interest in examining the effectiveness of alternative ways of delivering this therapy, for example in a group format (McCarthy, Hevey, Brogan, & Kelly, 2013). Some services have noted that there may be benefits of group treatment including normalisation of symptoms within a peer group, a social context within which skills can be practiced, the opportunity to learn from others, social pressure to comply with treatment and homework, and for some services the group format may be a better fit with respect to staff and financial resources (McEvoy, 2007; Wersebe, Sijbrandij, & Cuijpers, 2013).

Given the robust evidence base for Clark and Wells CT-SAD it is not surprising that it is now the focus of attention in regard to effectively adapting it for group intervention (Stangier, Heidenreich, Peitz, Lauterbach, & Clark, 2003). However, only a limited number of studies have adapted CT-SAD into varying forms of group therapy,

with differing degrees of adherence to CT-SAD and its treatment protocol. One study of 71 adults with SAD evaluated individual cognitive therapy, with a predominant CT-SAD treatment focus, in comparison to a group version of this program (Stangier et al., 2003). While both protocols aligned closely to CT-SAD, they did incorporate additional, specific cognitive work focussed on targeting assumptions, which is not part of Clark's CT-SAD standard protocol. Both treatments resulted in significant improvement in social anxiety on the Social Phobia Scale (SPS; Mattick & Clarke, 1998), Social Interaction Anxiety Scale (SIAS; Mattick & Clarke, 1998), and Social Phobia and Anxiety Inventory (SPAI; Turner, Beidel, Dancu, & Stanley, 1989). However, the individual format showed larger effect sizes at post-treatment: 0.90, 0.85, and 1.77 for the SPS, SIAS, and SPAI respectively for individual vs. 0.53, 0.53 and 0.60 for group (Stangier et al., 2003). On measures of mood, using the Beck Depression Inventory (BDI-II; Beck, Steer, & Brown, 1996), the group version showed significant improvement, whereas the individual format did not. The authors concluded that individual therapy was more effective than the group version in reducing the symptoms of social anxiety but noted that the therapists had limited training and that the study should be considered exploratory.

A further longitudinal study of 252 participants with SAD examined the effectiveness of a community-based group intervention, based on CT-SAD (McCarthy et al., 2013). However, McCarthy et al.'s intervention included some adaptations that were not consistent with Clark's CT-SAD protocol, such as cognitive restructuring and positive data logs. Measures were collected pre-treatment, post-treatment and at 12 months' follow-up and showed significant reductions in SAD symptoms and general mood measures. As the majority of participants were self-referred, findings may have been impacted by a less avoidant and more motivated subset. Further, while the Stangier

et al. (2003) and McCarthy et al. (2013) studies investigated CT-SAD in a group format and demonstrated positive findings, both studies indicated limitations relating to therapists, participants, and included variations from Clarks' standard CT-SAD protocol. Nonetheless, these findings support the proposition that CT-SAD can be incorporated into group treatment settings with positive outcomes.

A final point, Shafran et al. (2009) highlighted the commonly held criticism that CBT research trials may not be generalisable to routine settings and emphasised that this assumption may act as a barrier to the dissemination of evidence-based CBT. Shafran et al. highlighted that there was increasing evidence that research trials' findings are applicable to routine clinical care settings. Accordingly, Gunter and Whittal (2010) recommended that further effectiveness studies (i.e., non-research centre outcomes) were required to contribute to the argument that CBT for anxiety disorders should be widely disseminated.

Based on the saliency of this topic area and limitations of previous research, the current study examined the effectiveness of Clark's CT-SAD protocol developed into a group therapy intervention (GCT-SAD) in a routine, clinical setting with patients who had not responded to psychological and pharmacological interventions in the community. Based on the substantial evidence for the CT-SAD approach in an individual format at reducing the symptoms of anxiety, improving mood, and reducing self-focused attention and safety behaviours, it was hypothesised we would find similar effectiveness results for a newly-developed, group format in an out-patient clinic.

The following research hypotheses were tested; that after group treatment: (1) there would be a statistically significant decrease in social anxiety symptoms in participants, as measured by the SPS and the SIAS (Mattick & Clarke, 1998); (2) there would be a statistically significant decrease in depression symptoms in participants, as

measured by the BDI-II (Beck et al., 1996); (3) there would be a decrease in measures of self-focused attention and safety seeking behaviours (as measured using one item of the Social Phobia Weekly Summary Scale (SPWSS; Clark et al., 2003) and the Subtle Avoidance Frequency Examination (SAFE; Cuming et al., 2009) respectively), as these are key therapy targets in the CT-SAD model of therapy; and (4) there would be a reduction in measure of impaired functioning from the Work and Social Adjustment Scale (WSAS; Hafner & Marks, 1976).

## **Method**

### *Design*

This study analysed changes in SAD symptoms, depressive symptoms, self-focused attention, use of safety behaviours, and impaired functioning. Pre-treatment and post-treatment scores were compared using a quasi-experimental within-subjects design. Dependent variables analysed were SPS and SIAS scores, BDI-II scores, one item (c) of the SPWSS, SAFE scores, and WSAS scores.

### *Participants and setting*

Patients under the care of the XXXX Service (XXXX), New Zealand, were included in this study, which took place over four years (2010-2014). The XXXX is a government funded public mental health service that follows a stepped care approach encouraging General Practitioners (GPs) to treat mild anxiety presentations with psychoeducation and moderate anxiety being offered counselling, community support workers or medication. XXXX only accepts referrals for adults (aged 18-65) with moderate/severe anxiety disorders who have not responded to pharmacological and counselling interventions in the community. All patients had a 90 minute clinical



assessment semi-structure interview conducted by a senior clinician (i.e., clinical psychology, mental health nurse, social worker, occupational therapist) with substantial experience in assessing and treating anxiety disorders. This was followed by a review with a multidisciplinary team under the lead of a consultant psychiatrist for verification of a DSM-IV diagnosis.

After patients were assessed and accepted into the service, they were offered group or individual treatment; our research focus was only on those who accepted group treatment. GCT-SAD inclusion criteria required participants to have a primary diagnosis of SAD, to be suitable and willing to be involved in group treatment, and to be able to read English. Participants with substance dependence were not accepted into the service. Those with acute risk of suicide were treated with individual therapy.

The patients were not randomised into groups but entered them as they became available. Some patients were initially hesitant to participate in group therapy; however, clinicians provided education about the group to dispel misconceptions and demystify treatment, normalised their apprehension, and socialised patients to the approach. From a sample of 168 patients who fulfilled the inclusion criteria, nine were excluded from the current research (e.g., declined to participate in research, no pre-treatment session), resulting in a final sample of 159 who fulfilled the inclusion criteria. Of note, the participants in this study were affected by earthquakes which started in Christchurch from 2010. The first treatment group occurred between two major earthquakes and the remaining groups were exposed to ongoing aftershocks that occurred from 2010 onwards with diminishing frequency.

#### *Procedure and the group treatment*

Prior to treatment, participants attended an individual cognitive behavioural

assessment and formulation session. This session further confirmed the DSM-IV diagnosis of SAD, explained what GCT-SAD would involve, and developed their own personalised version of the Clark and Wells (1995) model of SAD and set treatment goals. Informed written consent for treatment and research, and pre-treatment questionnaires were completed at this time.

Participants then attended nine weekly, four-hour sessions of GCT-SAD, with groups consisting of seven to nine participants. Two clinicians (i.e., clinical psychologist, registered nurse, social worker, occupational therapist) specialising in the cognitive behavioural treatment of anxiety disorders were allocated to each group. At least one of the clinicians had run at least two social anxiety disorder groups previously and had previous experience in using the Clark and Wells treatment modules (Clark et al., 2004). All clinicians received supervision from senior clinical psychologists from within the team who were well versed in Clark's approach. In addition, the senior clinical psychologists provided additional group training on Clark's SAD approach and techniques to the ADS therapists running the groups. Group content was reviewed with the team over time to maintain adherence to the treatment model.

The GCT-SAD program was based on a series of modules that were originally developed for a self-study assisted version of the treatment (Clark et al., 2004) and were further adapted by the XXXX for group therapy. The modules were given to participants at the beginning of treatment as a reference for the content to be covered in the group and they were asked to complete the relevant modules as part of their weekly homework. GCT-SAD content included: socialising people to the Clark and Wells model; psychoeducation about anxiety and cognitive therapy; letting go of self-focused attention; attention training; reducing the use of safety behaviours; dropping of worry before entering social situations and going over past events; improving self-image; and

lastly, developing a therapy blueprint. Substantial time throughout GCT-SAD was focused on behavioural experiments personalised to each individual to test out cognitive predictions, and reduce safety behaviours and avoidance, and *in vivo* behavioural experiments were conducted during some sessions. These included practicing conversations while utilising external focus, visiting malls, and experiments where the person purposefully drew attention to themselves or acted in ways they believed to be unacceptable or that did not fit with their social rules (e.g., making a mistake, saying something disagreeable, or wearing silly hats). Participants were videoed giving speeches or other individually targeted behavioural experiments and these were played back to facilitate belief change through viewing themselves objectively in comparison to their internal, distorted self-image. Homework was integral; participants worked on behavioural experiments relating to their individual goals, practiced skills they had learnt, re-watched their videos, and completed the relevant modules. Within one to two weeks of each groups' completion, participants met with a group therapist to review their progress. Post-treatment questionnaires were completed individually.

Ethical approval for the study was provided by the New Zealand Health and Disability Ethics Committee (Ethics ref: URA/10/04/027).

### *Measures*

*Social Phobia Scale (SPS; Mattick & Clarke, 1998) and Social Interaction Anxiety Scale (SIAS; Mattick & Clarke, 1998)* were used to measure social anxiety. These widely used scales measure performance and interaction anxiety respectively. The 20-item SPS measures the fear of being observed by others, while the 19-item SIAS measures fears of general social interaction. Both scales adopt a 5-point response scale (0 = *not at all true* to 4 = *extremely true*). Thus, high scores represent greater levels of

social anxiety. Both the SPS ( $\alpha = .89$ ) and SIAS ( $\alpha = .93$ ) have high internal reliability (Cox, Ross, Swinson, & Direnfeld, 1998).

*Beck Depression Inventory-II (BDI-II; Beck et al., 1996)* measures depressive symptoms for the past two weeks, with 21-items rated on a 4-point response scale (0 = *I do not feel unhappy* to 3 = *I am so unhappy that I can't stand it*). Levels of severity are indicated as: Minimal 0 to 13; mild 14 to 19; moderate 20 to 28; and severe 29 to 63. The reliability and validity of the BDI-II is well established, with an internal reliability of .86 and test re-test reliability of .93 (McEvoy, 2007).

*Social Phobia Weekly Summary Scale; item c (SPWSS; Clark et al., 2003)*. A single item from the 6-item SPWSS was used: "For social situations in general, please choose a number from the scale below to show the extent to which your attention was focused on yourself or on the external situation in the last week." The item was scored on a 9-point scale (0 = *entirely externally-focused* to 8 = *entirely self-focused*) with higher scores representing a more self-focused attention. The SPWSS has good internal consistency ( $\alpha = .81$ ), and is sensitive to treatment effects (Clark et al., 2006; Clark et al., 2003).

*Subtle Avoidance Frequency Examination (SAFE; Cuming et al., 2009)* was used to measure the frequency of social safety behaviour use. The SAFE is a 32-item measure, adopting a 5-point response scale (1 = *never* to 5 = *always*). The three main factors within this scale are: Inhibiting/restricting behaviours designed to avoid attracting attention (e.g., "remain silent", "avoid eye contact"); active behaviours aimed at enhancing self-presentation (e.g., "rehearse sentences in your mind"); and physical symptom management behaviours (e.g., "wear clothes or make-up to hide blushing"). The scale shows high internal reliability .95, and clear convergent and divergent validity (Moscovitch et al., 2013).

*Work and Social Adjustment Scale (WSAS; Hafner & Marks, 1976)* was employed to measure the degree of interference caused by symptoms. The WSAS is a 5-item measure, adopting a 9-point response scale (0 = *not at all* to 8 = *very severely*). The 5-items include work, home management, social leisure activities, private leisure activities, and family and relationships. The scale has a possible total score of 40, with scores above 20 suggesting moderate to severe pathology (Mundt, Marks, Shear, & Greist, 2002). The measure has shown adequate test-retest reliability of .73, (Mundt et al., 2002), and good internal consistency .80 (Allen et al., 2009).

For the current sample, questionnaire internal consistencies (with the exception of the WSAS  $\alpha = .67$ ) were all satisfactory (SPS  $\alpha = .92$ , SIAS  $\alpha = .84$ , BDI-II  $\alpha = .92$ , SPWSS  $\alpha = .73$ , SAFE  $\alpha = .88$ ). The Cronbach's alpha for the WSAS, a 5-item scale, may have been due to the limited number of items in the scale. The value of the alpha is dependent on the number of items in the scale and as the number of items in a scale increases the alpha will increase (Field, 2013). Further, the WSAS has shown good internal reliability in other studies (Allen et al., 2009). Therefore, it was decided to leave the questionnaire intact rather than deleting items in an attempt to increase the alpha.

#### *Data analyses*

SPSS (version 24) was used for statistical analyses. The self-reported data consisted of anxiety levels as represented by scores on the SPS and SIAS; depression levels as represented by BDI-II scores; levels of self-focus as reported by the item c score of the SPWSS scale; levels of safety seeking behaviours as represented by SAFE scores; and functioning as represented by the WSAS. Data were manually entered into SPSS. To ensure accuracy of data-entry a 10% audit, comparing the original data set provided by XXXX against the SPSS data set, was conducted. With regard to missing

data, scale data were included if 95% or more of the scale had been completed. While there is little consensus in the literature regarding an acceptable missing data cut-off rate (Dong & Peng, 2013), Bennett (2001) maintains that when the amount of missing data is greater than 10%, statistical analyses may be biased. Therefore, the exclusion rate of 5% or less was considered to be an acceptable range. Adjustments for missing data, for participants with missing data but not excluded, were made using a prorated methodology.

Data screening was conducted to ensure that appropriate assumptions were met. The Shapiro-Wilk test indicated a possible breach in normality in one instance, SPS post-treatment; however, visual inspection of the normal Q-Q plot and histogram for this scale confirmed normality. Further, it was noted that care must be taken when using the Shapiro-Wilk test on larger sample sizes as significant results may occur for even slight deviations (Field, 2013). In consideration of the robustness of the data, there was no need to conduct transformations.

Dependent samples *t*-tests require normality of the differences between the scores on each dependent variable. All variables showed appropriate skewness and kurtosis values. Further, the difference scores between all variables were normally distributed, as assessed by visual inspection of the normal Q-Q plots. Nine outliers were detected, as assessed by visual inspection of box-plots. Inspection of these values did not reveal them to be extreme and they were kept in the analysis.

Pre-treatment completer / non-completer group equivalence on demographic and psychological measures was assessed by *t*-tests and Chi-square analysis as appropriate. Paired samples *t*-tests were used to compare differences pre- and post-treatment in completers' scores. An *a priori* decision was to define completion as an adequate dose of therapy as attendance of at least seven out of nine treatments sessions based on

previous research at XXXX and studies on group therapy (Bell, Colhoun, Carter, & Frampton, 2012; Sloan, Feinstein, Gallagher, Beck, & Keane, 2013). To ensure that effect sizes were not artificially inflated due to experimental mortality type effects, effect sizes were calculated using both completers' and intention-to-treat (ITT) data. In accordance with previous research (e.g., McEvoy, 2007), effect sizes were computed using the formula (pre-treatment mean – post-treatment mean) / pre-treatment standard deviation. Effect sizes magnitude interpretations were based on Cohen's  $d$ , with  $d = 0.20$  considered small effect,  $d = 0.50$  considered medium effect, and  $d = 0.80$  considered large effect (Cohen, 1988). Power ( $1 - \beta$ ) was set at .80 and alpha at .05.

## Results

### *Sample characteristics*

Participants ( $n = 159$ ) were classified into completers and non-completers (see above definition); 101 (64%) participants were deemed treatment completers ( $N = 101$ ,  $M_{\text{age}} = 34.1$  years,  $SD_{\text{age}} = 10.8$  years, range 19 - 59 years; 53% female) and 58 (36%) participants were deemed non-completers ( $M_{\text{age}} = 33.6$  years,  $SD_{\text{age}} = 10.1$  years, range 20 - 59 years; 52% female) (see Figure 1). Of the non-completers, 14 participants had dropped-out after the initial assessment; a further seven after session 1; five after session 2; five after session 3; eight after session 4; six after session 5; and 13 after session 6. Of the completer group, 80% were NZ/European, 5% Maori, and 15% other. Nearly a third of completers, 28%, were cohabitating or married, 66% had a high school education, 16% had tertiary education, 13% had a trade or technical certificate, and 5% had primary education only. Additionally, 45% of completers were unemployed. Reflecting the severity and treatment resistant state of the participants, all were on psychotropic medication, predominantly anti-depressants, two-thirds of whom did not change their medication during the course of GCT-SAD. Of the treatment completers,

84% participants reported no comorbidities, 4% reported generalised anxiety disorder, 4% panic disorder with agoraphobia, 3% depressive disorder, 3% obsessive compulsive disorder, 1% panic disorder, and 1% reporting obsessive compulsive disorder with generalised anxiety disorder.

Completers ( $n = 99$ ) were not significantly different to non-completers ( $n = 58$ ) on any demographic or psychological measure ( $p > .05$ ). Reasons cited for attrition from the study were psychosocial issues (lack of transport, loss of housing, finding work, illness), or psychological issues (too anxious to attend).




Figure 1. Flowchart of participant attrition.

### *Descriptive statistics*

This study analysed changes in SAD symptoms, depressive symptoms, self-focused attention, use of safety behaviours, and impaired functioning. Pre-treatment and post-treatment scores were compared using a quasi-experimental within-subjects design. Dependent variables analysed were SPS and SIAS scores, BDI-II scores, one item of the



SPWSS, SAFE scores, and WSAS scores.

*Pre-treatment and post-treatment comparisons*

Means and standard deviations for all dependent variables, pre- and post-treatment are shown in Table 1. Mean scores of 45.31 and 53.16 on the SPS and the SIAS respectively indicate high levels of social anxiety. BDI-II mean score of 25.8 indicate moderate levels of depression and 24.01 on the WSAS suggest moderately severe pathology which gives an indication of the severity of this sample.

Significant and meaningful improvements (as indicated by moderate to large effect sizes) were demonstrated on all measures. The results demonstrated that overall the GCT-SAD participants had statistically significant decreases in symptoms of social anxiety (SPS and SIAS; large effect sizes), depression (BDI-II; medium effect size), self-focused attention (SPWSS item c; medium effect size) and safety behaviours (SAFE;

**Table 1.**

*Pre-and Post-Treatment Means and Standard Deviations for Dependent Variables, and Completer and Intention-to-Treat Effect Sizes*

Test variable		Pre-treatment		Post-treatment		Difference		
		<i>M (SD)</i>	<i>N</i> <sup>†</sup>	<i>M (SD)</i>	<i>N</i> <sup>†</sup>	<i>df</i>	<i>t</i>	<i>d</i>
<b>SPS</b>	ITT	44.17 (14.37)	156					
	Completers	45.31 (13.43)	80	29.85 (14.06)	80	79	11.98	1.00
	Non-completers	41.45 (15.90)	56					
<b>SIAS</b>	ITT	52.36 (10.28)	155					
	Completers	53.16 (9.79)	82	38.76 (13.15)	82	81	11.37	1.32
	Non-completers	51.02 (10.54)	55					
<b>BDI-II</b>	ITT	26.92 (11.94)	154					
	Completers	25.80 (10.85)	76	18.45 (11.61)	76	75	6.65	0.71
	Non-completers	28.41 (12.96)	55					
<b>SPWSS(c)</b>	ITT	5.03 (1.52)	157					
	Completers	5.16 (1.50)	81	3.84 (1.56)	81	80	5.47	0.78
	Non-completers	4.93 (1.51)	57					
<b>SAFE</b>	ITT	93.94 (18.55)	155					
	Completers	93.27 (17.83)	82	76.81 (19.02)	82	81	8.50	0.92
	Non-completers	95.18 (19.78)	54					
<b>WSAS</b>	ITT	23.64 (6.81)	151					
	Completers	24.01 (6.65)	77	19.73 (7.67)	77	76	6.53	0.57
	Non-completers	22.91 (7.06)	55					

large effect size) and significant improvement in occupational, social and domestic functioning (WSAS; medium effect size).

*Note.* SPS = Social Phobia Scale; SIAS = Social Interaction Anxiety Scale; BDI-II = Beck Depression Inventory II; SPWSS (c) = Social Phobia Weekly Summary Scale Item c; SAFE = Subtle Avoidance Frequency Scale; WSAS = Work and Social Adjustment Scale. Effect sizes were calculated using an Intention-to-Treat (ITT) approach including all participants' data; pre- and post-treatment means (standard deviations) were calculated using completers' data only. Initial group equivalents between those that went on to be completers and those who were non-completers was assumed by non-significant ( $p > .05$ ) independent t-tests at pre-treatment. \*  $p < .001$ . †While 101 participants gave useful data at both pre and post, not all participants provided responses across all measures at both time points, thus  $n < 101$ . Further, not all ITT ( $N = 159$ ) and non-completers ( $n = 58$ ) provided responses at pre-treatment.

## Discussion

The aim of the current study was to determine the effectiveness of Clark and Wells CT-SAD developed into a group therapy intervention, GCT-SAD, in a routine clinical setting. It was hypothesised that after group treatment: (1) There would be a statistically significant decrease in social anxiety symptoms in participants; (2) there would be a statistically significant decrease in depression symptoms in participants; (3) there would be a decrease in measures of self-focused attention and safety seeking behaviours; and (4) there would be a reduction of impaired functioning. The present findings strongly suggest that this therapy format was effective with individuals suffering from severe SAD (with large effect size). The specific social anxiety disorder measures demonstrated greater change than the general mood measures, with the largest gains on the SPS ( $d = 1.0$ ) and SIAS ( $d = 1.32$ ) scales. This result does raise the question of whether the other measures of BDI-II, SPWSS(c), SAFE, and WSAS weren't so sensitive to change, or that the treatment did not produce such large improvements for those symptoms as compared to the social anxiety disorder symptoms. Based on the reported utility of the measures, we were confident the result was more due to the effect of intervention, rather than insensitive measurement issues.

Regarding our first hypothesis, there was a significant decrease in SAD. These improvements are noteworthy as the participants had not responded well to previous

treatments; the participants for this investigation were only accepted as referrals if they had moderate/severe anxiety disorders and had not responded to pharmacological and counselling interventions in the community. It is also important to note that the participants' high baseline levels of social anxiety were comparable to other studies (Clark et al., 2003; Gaston, Abbott, Rapee, & Neary, 2006; Mörtberg, Karlsson, Fyring, & Sundin, 2006; Stangier et al., 2003). These high baseline levels of severity potentially allowed more room for improvement, consequently, making it easier to get larger effect sizes; although baseline severity does not always have a linear relationship with degree of improvement (Kirsch et al., 2008). Nevertheless, the effect sizes were as high, or higher than, other group treatment studies (e.g., McCarthy et al., 2013, SPS  $d = 0.87$ , SIAS  $d = .97$ ; McEvoy, 2007, SPS  $d = 1.00$ , SIAS  $d = 1.10$ ). Further, GCT-SAD compared favourably to several individual studies for SAD (Lincoln et al., 2003; Stangier et al., 2003) but did not achieve the effect sizes demonstrated by CT-SAD (e.g., Mayo-Wilson et al., 2014) suggesting that GCT-SAD could be further improved. Overall, results indicate that our version of GCT-SAD is effective for significantly reducing anxiety symptoms in severe and treatment resistant patients.

Anxiety and depressive disorders frequently occur together (Spijker, Muntingh, & Batelaan, 2020); therefore, pragmatically it is important when measuring the effectiveness of anxiety treatment to evaluate treatments' impact on depression. Thus, with regard to the second hypothesis, the treatment process significantly decreased participants' levels of depression. At pre-treatment, participants were in the moderately depressed range (20-28), with a BDI-II mean of 25.80, compared to other group and individual studies where participants started treatment with a mild BDI score (14-19; Mörtberg et al., 2006; Stangier et al., 2003, Lincoln et al., 2003). At post-treatment, participants BDI-II scores had shifted to a mild level with a moderate effect size of 0.7

which is consistent with findings from other group treatment studies (McCarthy et al., 2013; McEvoy, 2007; Mörtberg et al., 2006; Stangier et al., 2003) and provides further evidence that directing treatment at an anxiety disorder often improves comorbid depression (Spijker, Muntingh, & Batelaan, 2020). Effect sizes were lower for depression than social anxiety measures, likely due to GCT-SAD targeting anxiety symptoms rather than mood but nonetheless suggests that as peoples' social anxiety improves their mood may also improve to a lesser degree.

In relation to the third hypothesis, there were significant decreases in self-focused attention and safety seeking behaviour associated with the improvement in social anxiety measures. CT-SAD specifically targets these maintaining factors as their reduction appears to assist in contradicting inaccurate negative beliefs and may reduce the possibility of feared outcomes occurring. It is likely that some of the specific procedures that have shown to be effective in reducing the symptoms of SAD in other studies utilising the Clark and Wells approach (Clark et al., 2006), such as video feedback, experiential demonstration of the adverse effects of self-focused attention and safety behaviours, and imagery modification, have had similar effects in GCT-SAD. Reduction in self-focused attention had a moderate effect size, and does not compare well with the Mörtberg, Hoffart, Boecking, and Clark (2013) study that had a large effect size for the SPWSS item c. While baseline levels of self-focus were similar in both studies, it is important to note the Mörtberg et al. (2013) efficacy study utilised an individual therapy approach over 16 weeks versus our group treatment duration of nine weeks. The specific individual focus and a longer time-frame to practice the skill may explain the difference in the effect size between the two studies. However, this highlights that improving the method of cognitive therapy's focus on reducing self-focused attention in a group format needs further development and consideration.

The significant decrease in safety behaviours resulted in a large effect size in our study. As well as preventing effective processing of the social situation, it has been proposed that a reduction in safety behaviours may reduce self-focus (Bögels & Mansell, 2004; Clark & Wells, 1995; Rapee & Heimberg, 1997), although no mediational analysis was conducted in the present study to confirm this possibility.

Regarding the fourth hypothesis, there were significant decreases in functional impairment following treatment, with a moderate effect size. This clinical characteristic has been found to be predictive of a stable, persisting course of SAD (Beesdo-Baum et al., 2012), and a reduction indicates the possibility of a return towards healthy functioning. SAD is known to have a relatively early age of onset and is associated with significant impairment in work and social functioning (Rapaport, Clary, Fayyad, & Endicott, 2005). While our study looked at changes pre- and post-treatment, allowing for perceived, self-reported improvement to be measured, it would have been useful to have had a clinical measurement of functioning to support these results.

Importantly, our findings for the effectiveness of a group version of CT-SAD (i.e., GCT-SAD) in a routine out-patient clinic, were comparable to previous effectiveness and routine care treatment studies (McEvoy, 2007; McCarthy et al., 2013). Our effect sizes for all measures were towards the higher scores found in previous research. This is notable, given that all patients had not responded to previous treatment for SAD and although it is unlikely that they would have received prior evidence-based treatment for SAD, it may have reduced the placebo effect prior to their treatment at ADS. Furthermore, they were also exposed to a significant natural disaster, including aftershocks, while experiencing SAD and during their treatment.

*Limitations and future directions*

Strengths of the current study were that it used a population of clinically referred participants with SAD who had not responded to previous treatments, it had a large sample size, and treatments were conducted in a naturalistic, routine care setting. These factors are encouraging for generalisability of our results.

Several limitations, however, must be considered. First, this study was impacted by a number of disruptions; the first group occurred between two major earthquakes, there were ongoing aftershocks throughout the treatment process for all groups, resulting in sessions being conducted in a range of settings due to the loss of the initial treatment building, and the location of non-clinic behavioural experiments had to be moved due to damage to the inner city. It is possible that these disruptions and other earthquake-related consequences contributed to the drop-out rate of 36.5%. While high drop-out rates are not uncommon in SAD literature (Bados, Balaguer, & Saldaña, 2007; Fedoroff & Taylor, 2001) with some studies reporting drop-out rates as high as 43.8% (Bados et al., 2007), a number of trials by Clark and colleagues, and other researchers, have demonstrated lower drop-out rates (Clark et al., 2006; Clark et al., 2003; McCarthy et al., 2013). However, Clark et al. (2006) considered completers as attending at least half of the therapy sessions available; whereas, in the present study we defined completers as completing seven of nine (75%) sessions. Thus, different definitions of completers may contribute to the variability of drop-out rates. Nevertheless, further attention needs to be given to improving treatment retention in future SAD group therapy contexts. Also, given the constrictions on the extent of information given at referral, the exact nature of previous psychological treatments was unable to be determined. In future, gathering this information may be informative in terms of drop-out characteristics and in determining for whom GCT-SAD may be most appropriate.

Secondly, the number of ADS patients who declined group treatment following their initial assessment is not known. Individual or group treatment is decided collaboratively between the patient and the therapist and is affected by a number of factors including clients' availability for the group timetable, group start dates and clients' ability to wait, and clients' preference for individual or group format. However, because ADS' process does not require group treatment as the first treatment offered, it is difficult to quantify the number who actually chose individual over group treatment. Consequently, this should be recorded more accurately in future studies.

Thirdly, this study did not have a control group and was not a randomised controlled comparison of individual compared with group treatment, therefore, caution should be exercised in interpreting the current results. Fourth, all data were self-reported and self-focused attention was measured by only one item. Although the use of self-report scales is common in clinical practice, such measures may be subject to biased responding (Sato & Kawahara, 2011) and future research could benefit from the addition of clinician rated scales. Fifth, as there was no follow up data, the results only show short-term effects and do not allow for any conclusions regarding the maintenance of treatment gains. Future studies, including follow-up results, would assist in understanding the longer-term impact of this form of group treatment. Future research with larger samples could also control for depression when evaluating changes in the severity of social anxiety symptoms.

Lastly, although the treatment was manualised and the team had ongoing processes for supervision and training, there were no formal measures of therapy fidelity or therapist drift.

### *Conclusions*

Given the large sample size and positive results, this study suggests that GCT-

SAD is effective in routine, clinical care and with severe and treatment resistant patients. Further, our findings contribute to the growing literature supporting that outcomes from SAD research trials are generalisable to clinical practice. In addition, while it appears that our GCT-SAD format, most closely aligns to Clark's cognitive therapy approach in comparison to other studies, there is scope for improvement, and research into the mediators of group treatment would be useful, particularly further research into anticipatory and post-event processing and self-focus, as these have been found to be key mediators in previous research (Hedman et al., 2013). Lastly, it was noted that GCT-SAD effect sizes were lower than CT-SAD effect sizes previously reported, and further comparisons between GCT-SAD and CT-SAD in a routine, clinical setting may be advantageous for the ongoing improvement and development of the group protocol.



### **Acknowledgements**

We would like to thank all of the participants of this study and the support staff at the Anxiety Disorders Service and Dr Ben Lane at USC for research assistance.

### **Declaration of Interest & Financial Support**

None of the authors of this paper have any conflict of interest with respect to this publication. This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

### References

- Albano, A. M., & Hayward, C. (2004). Social anxiety disorder. In T. Ollendick & J. March (Eds.), *Phobic and anxiety disorders in children and adolescents: A clinician's guide to effective psychosocial and pharmacological interventions* (pp. 198-235). New York:Oxford University Press.
- Allen, L. B., White, K. S., Barlow, D. H., Shear, M. K., Gorman, J. M., & Woods, S. W. (2009). Cognitive-behavior therapy (CBT) for panic disorder: Relationship of anxiety and depression comorbidity with treatment outcome. *Journal of Psychopathology and Behavioral Assessment, 32*, 185-192. doi:10.1007/s10862-009-9151-3
- American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders (5th ed.)*. Arlington, VA: American Psychiatric Publishing.
- Bados, A., Balaguer, G., & Saldaña, C. (2007). The efficacy of cognitive-behavioral therapy and the problem of drop-out. *Journal of Clinical Psychology, 63* (6), 585-592. doi:10.1002/jclp.20368
- Beck, A. T., Steer, R. A., & Brown, G. K. (1996). *Manual for the Beck Depression Inventory-II*. San Antonio, TX: Psychological Corporation.
- Beesdo-Baum, K., Knappe, S., Fehm, L., Höfler, M., Lieb, R., Hofmann, S. G., & Wittchen, H. U. (2012). The natural course of social anxiety disorder among adolescents and young adults. *Acta Psychiatrica Scandinavica, 126*, 411-425. doi:10.1111/j.1600-0447.2012.01886.x
- Bell, C., Colhoun, H., Carter, F., & Frampton, C. (2012). Effectiveness of Computerised Cognitive Behavioural Therapy for Anxiety Disorders in Secondary Care. *Australian and New Zealand Journal of Psychiatry, 46*, 630-640. doi:10.1177/0004867412437345.

- Bennett, D. A. (2001). How can I deal with missing data in my study? *Australian and New Zealand Journal of Public Health*, 25, 464. doi:10.1111/j.1467-842X.2001.tb00294.x
- Bögels, S. M., & Mansell, W. (2004). Attention processes in the maintenance and treatment of social phobia: Hypervigilance, avoidance and self-focused attention. *Clinical Psychology Review*, 24, 827-856. doi:10.1016/j.cpr.2004.06.005
- Clark, D. M., Deale, A., Grey, N., Liness, S., Murray, H., Turner, C., & Wild, J. (2004). *Brief Cognitive Therapy for Social Phobia*. Unpublished Manual. London: Centre for Anxiety Disorders and Trauma, Maudsley Hospital & Department of Psychology, Institute of Psychiatry, King's College London.
- Clark, D. M., Ehlers, A., Hackmann, A., McManus, F., Fennell, M., Grey, N., . . . Wild, J. (2006). Cognitive therapy versus exposure and applied relaxation in social phobia: A randomized controlled trial. *Journal of Consulting and Clinical Psychology*, 74, 568-578. doi:10.1037/0022-006X.74.3.568
- Clark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., . . . Louis, B. (2003). Cognitive therapy versus Fluoxetine in generalized social phobia: A randomized placebo-controlled trial. *Journal of Consulting and Clinical Psychology*, 71, 1058-1067. doi:10.1037/0022-006X.71.6.1058
- Clark, D. M., & Wells, A. (1995). A cognitive model of social phobia. In R. Heimberg (Ed.), *Social phobia: Diagnosis, assessment, and treatment* (pp. 69-93). New York: Guilford Press.
- Cohen, J. (1988). *Statistical power analysis for the behavioral sciences* (2nd ed.) New York: Routledge.

- Cox, B. J., Ross, L., Swinson, R. P., & Direnfeld, D. M. (1998). A comparison of social phobia outcome measures in cognitive-behavioral group therapy. *Behavior Modification, 22*, 285-297. doi:10.1177/01454455980223004
- Cuming, S., Rapee, R. M., Kemp, N., Abbott, M. J., Peters, L., & Gaston, J. E. (2009). A self-report measure of subtle avoidance and safety behaviors relevant to social anxiety: Development and psychometric properties. *Journal of Anxiety Disorders, 23*, 879-883. doi:10.1016/j.janxdis.2009.05.002
- Dong, Y., & Peng, C.-Y. J. (2013). Principled missing data methods for researchers. *SpringerPlus, 2*, 1-17. doi:10.1186/2193-1801-2-222
- Fedoroff, I. C., & Taylor, S. (2001). Psychological and pharmacological treatments of social phobia: A meta-analysis. *Journal of Clinical Psychopharmacology, 3*, 311-324.
- Field, A. (2013). *Discovering statistics using IBM SPSS statistics*. London: Sage Publications Ltd.
- Gaston, J. E., Abbott, M. J., Rapee, R. M., & Neary, S. A. (2006). Do empirically supported treatments generalize to private practice? A benchmark study of a cognitive-behavioural group treatment programme for social phobia. *British Journal of Clinical Psychology, 45*, 33-48. doi:10.1348/014466505X35146
- Goldin, P. R., Morrison, A., Jazaieri, H., Brozovich, F., Heimberg, R., & Gross, J. J. (2016). Group CBT versus MBSR for social anxiety disorder: A randomized controlled trial. *Journal of Consulting and Clinical Psychology, 84*, 427-437. doi:10.1037/ccp0000092
- Gunter, R. W., & Whittal, M. L. (2010). Dissemination of cognitive-behavioral treatments for anxiety disorders: Overcoming barriers and improving patient access. *Clinical Psychology Review, 30*, 194-202. doi:10.1016/j.cpr.2009.11.001

- Hafner, R. J., & Marks, I. M. (1976). Exposure in vivo of agoraphobics: Contributions of diazepam, group exposure, and anxiety evocation. *Psychological Medicine*, *6*, 71-88. doi:10.1017/S0033291700007510
- Hauksson, P., Ingibergsdóttir, S., Gunnarsdóttir, T., & Jónsdóttir, I. H. (2017): Effectiveness of cognitive behaviour therapy for treatment-resistant depression with psychiatric comorbidity: Comparison of individual versus group CBT in an interdisciplinary rehabilitation setting, *Nordic Journal of Psychiatry*, *71*, 465-472. doi: 10.1080/08039488.2017.1331263
- Hedman, E., Mörtberg, E., Hesser, H., Clark, D. M., Lekander, M., Andersson, E., & Ljótsson, B. (2013). Mediators in psychological treatment of social anxiety disorder: Individual cognitive therapy compared to cognitive behavioral group therapy. *Behaviour Research and Therapy*, *51*, 696-705. doi:10.1016/j.brat.2013.07.006
- Iancu, I., Levin, J., Hermesh, H., Dannon, P., Poreh, A., Ben-Yehuda, Y., . . . Kotler, M. (2006). Social phobia symptoms: Prevalence, sociodemographic correlates, and overlap with specific phobia symptoms. *Comprehensive Psychiatry*, *47*, 399-405. doi:10.1016/j.comppsy.2006.01.008
- Kirsch I., Deacon, B. J., Huedo-Medina, T. B, Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. *PLoS Med* *5*(2), e45. Retrieved from: <https://doi.org/10.1371/journal.pmed.0050045>
- Lincoln, T. M., Rief, W., Hahlweg, K., Frank, M., von Witzleben, I., Schroeder, B., & Fiegenbaum, W. (2003). Effectiveness of an empirically supported treatment for social phobia in the field. *Behaviour Research and Therapy*, *41*, 1251-1269. doi:10.1016/S0005-7967(03)00038-X

- Mattick, R. P., & Clarke, J. C. (1998). Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. *Behaviour Research and Therapy*, *36*, 455-470. doi:0.1016/S0005-7967(97)10031-6
- Mavranzouli, I., Mayo-Wilson, E., Dias, S., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2015). The cost effectiveness of psychological and pharmacological interventions for social anxiety disorder: A model-based economic analysis. *PLoS ONE* 10(10): e0140704. doi:10.1371/journal.pone.0140704
- Mayo-Wilson, E., Dias, S., Mavranzouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2014). Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. *The Lancet Psychiatry*, *1*, 368–376. doi:10.1016/S2215-0366(14)70329-3
- McCarthy, O., Hevey, D., Brogan, A., & Kelly, B. D. (2013). Effectiveness of a cognitive behavioural group therapy (CBGT) for social anxiety disorder: Immediate and long-term benefits. *The Cognitive Behaviour Therapist*, *6*, 1-13. doi:10.1017/S1754470X13000111
- McEvoy, P. (2007). Effectiveness of cognitive behavioural group therapy for social phobia in a community clinic: A benchmarking study. *Behaviour Research and Therapy*, *45*, 3030-3040. doi:10.1016/j.brat.2007.08.002
- Ministry of Health (2012). *The Health of NZ Adults 2011/12: Key findings of the New Zealand Health Survey*. Wellington: Ministry of Health.
- Mörtberg, E., Hoffart, A., Boecking, B., & Clark, D. M. (2013). Shifting the focus of one's attention mediates improvement in cognitive therapy for social anxiety disorder. *Behavioural and Cognitive Psychotherapy*, *43*, 63-73. doi:10.1017/S1352465813000738

- Mörtberg, E., Karlsson, A., Fyring, C., & Sundin, Ö. (2006). Intensive cognitive-behavioral group treatment (CBGT) of social phobia: A randomized controlled study. *Journal of Anxiety Disorders, 20*, 646-660. doi:10.1016/j.janxdis.2005.07.005
- Moscovitch, D. A., Rowa, K., Paulitzki, J. R., Ierullo, M. D., Chiang, B., Antony, M. M., & McCabe, R. E. (2013). Self-portrayal concerns and their relation to safety behaviors and negative affect in social anxiety disorder. *Behaviour Research and Therapy, 51*, 476-486. doi:10.1016/j.brat.2013.05.002
- Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. M. (2002). The Work and Social Adjustment Scale: A simple measure of impairment in functioning. *The British Journal of Psychiatry, 180*, 461-464. doi:10.1192/bjp.180.5.461
- National Institute for Health and Care Excellence (2013). *Social anxiety disorder: Recognition, assessment and treatment of social anxiety disorder*. London: Clinical Guideline, No. 159. Retrieved from <https://www.nice.org.uk/guidance/cg159>
- Ollendick, T. H., & Hirshfeld-Becker, D. R. (2002). The developmental psychopathology of social anxiety disorder. *Biological Psychiatry, 51*, 44-58. [https://doi.org/10.1016/S0006-3223\(01\)01305-1](https://doi.org/10.1016/S0006-3223(01)01305-1)
- Rapaport, M. H., Clary, C., Fayyad, R., & Endicott, J. (2005). Quality-of-life impairment in depressive and anxiety disorders. *American Journal of Psychiatry, 162*, 1171-1178. doi:10.1176/appi.ajp.162.6.1171
- Rapee, R. M., & Heimberg, R. (1997). A cognitive-behavioral model of anxiety in social phobia. *Behaviour Research and Therapy, 35*, 741-756. doi:10.1016/S0005-7967(97)00022-3

- Ruscio, A. M., Brown, T. A., Chiu, W. T., Sareen, J., Stein, M. B., & Kessler, R. C. (2008). Social fears and social phobia in the USA: Results from the National Comorbidity Survey Replication. *Psychological Medicine, 38*, 15-28.  
doi:10.1017/S0033291707001699
- Sato, H., & Kawahara, J. (2011). Selective bias in retrospective self-reports of negative mood states. *Anxiety, Stress & Coping, 24*, 359-367.  
doi:10.1080/10615806.2010.543132
- Shafran, R., Clark, D. M., Fairburn, C. G., Arntz, A., Barlow, D. H., Ehlers, A., ... & Wilson, G. T. (2009). Mind the gap: Improving the dissemination of CBT. *Behaviour Research and Therapy, 47*, 902-909.  
doi:10.1016/j.brat.2009.07.003
- Slade, T., Johnston, A., Oakley Browne, M. A., Andrews, G., & Whiteford, H. (2009). 2007 National Survey of Mental Health and Wellbeing: Methods and key findings. *Australian & New Zealand Journal of Psychiatry, 43*, 594-605.  
doi:10.1080/00048670902970882
- Sloan, D. M., Feinstein, B. A., Gallagher, M. W., Beck, J. G., & Keane, T. M. (2013). Efficacy of group treatment for posttraumatic stress disorder symptoms: A meta-analysis. *Psychological Trauma: Theory, Research, Practice, and Policy, 5*, 176-183. doi: 10.1037/a0026291
- Sochting I. (2014). Cognitive behavioral group therapy: Challenges and opportunities. Chichester. UK: Wiley.
- Spijker, J., Muntingh, A., & Batelaan, N. (2020). Advice for clinicians on how to treat comorbid anxiety and depression. *JAMA Psychiatry*. Advance online publication. doi:10.1001/jamapsychiatry.2020.0601



Stangier, U., Heidenreich, T., Peitz, M., Lauterbach, W., & Clark, D. M. (2003).

Cognitive therapy for social phobia: Individual versus group treatment.

*Behaviour Research and Therapy*, *41*, 991-1007. doi:10.1016/S0005-

7967(02)00176-6

Turner, S. M., Beidel, D. C., Dancu, C. V., & Stanley, M. A. (1989). An empirically

derived inventory to measure social fears and anxiety: The Social Phobia and

Anxiety Inventory. *Psychological Assessment: A Journal of Consulting and*

*Clinical Psychology*, *1*, 35-40. doi:10.1037/1040-3590.1.1.35

Wersebe, H., Sijbrandij, M., & Cuijpers, P. (2013). Psychological group-treatments of

social anxiety disorder: A meta-analysis. *Plos-One*, *8*, 1-7.

doi:10.1371/journal.pone.0079034

Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., ... &

Steinhausen, H. C. (2011). The size and burden of mental disorders and other

disorders of the brain in Europe 2010. *European Neuropsychopharmacology*, *21*,

655-679. doi:10.1016/j.euroneuro.2011.07.018